DNTH - Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. Logo

DNTH - Dianthus Therapeutics Inc.

https://dianthustx.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart ( DNTH103 ) in Generalized Myasthenia Gravis
GlobeNewswire • 1 week ago • score: 0.29
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. ( Nasdaq: DNTH ) , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference ...
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-09 (Snapshot)

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.

52W High
$32.27
52W Low
$13.37
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
N/A
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-7.35
EV/Revenue (<3 favorable)
122.98
P/S (TTM) (<3 favorable)
175.73
P/B (<3 favorable)
2.81
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
7.86%
Institutions (25–75% balanced)
122.99%
Shares Outstanding
32,188,300
Float
13,459,200
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
4,854,000
Gross Profit (TTM)
4,854,000
EPS (TTM)
-3.27
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-180.97%
ROE (TTM) (>15% strong)
-0.35%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.90
Momentum
Bearish momentum
Value
1.4753
Previous
1.2800
Trend
Rising
Signal Cross
No cross
As of
Sep. 05, 2025